Products
NILOGEN Nilotinib 200 MG
NILOGEN Nilotinib 200 MG
Generic name: Nilotinib (as hydrochloride monohydrate)
The brand name of hydrogen Oncology: Nilogen
Drug classification: Antineoplastic
Pharmaceutical form: capsule
Drug dose: 200 mg
packing: 30 capsules
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- Adult and pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
- Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib
- Pediatric patients ≥1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy
TRIFLUGEN TERIFIUNOMIDE 14 MG
TRIFLUGEN TERIFIUNOMIDE
Generic name: Teriflunomide
The brand name of hydrogen Oncology: Triflugen
Drug classification: MS
Pharmaceutical form: tablet
Drug dose: 14 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: For the treatment of relapsing forms of multiple sclerosis (MS), including:
- Clinically isolated syndrome
- Relapsing-remitting disease
- Active secondary progressive disease in adults.
Note: It is not known if Teriflunomide is safe and effective in children.
ABIRAGEN Abiraterone acetate
ABIRAGEN Abiraterone acetate 250 MG
Generic name: Abiraterone acetate
The brand name of hydrogen Oncology: Abiragen
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 250 mg
packing: 120 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: Abiraterone is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with:
- Metastatic castration-resistant prostate cancer (CRPC)
- Metastatic high-risk castration-sensitive prostate cancer (CSPC)
Note: It is not known if Abiragen® is safe and effective in females or children
RUXOGEN Ruxolitinib 5 MG
RUXOGEN Ruxolitinib 5 MG
Generic name: Ruxolitinib
The brand name of hydrogen Oncology: RUXOGEN
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 5 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: for the treatment of certain types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Indications:
- Myelofibrosis
- Polycythemia vera
- Graft-versus-host disease (GVHD)
SUNIGEN Sunitinib 25 MG
SUNIGEN Sunitinib 25 MG
Generic name: Sunitinib (as malate or as base)
The brand name of hydrogen Oncology: Sunigen
Drug classification: Antineoplastic
Pharmaceutical form: capsule
Drug dose: 25 mg
packing: 30 capsule
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- The treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate
- The treatment of advanced renal cell carcinoma (RCC)
- The adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy
- The treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease
PALBOGEN Palbociclib 125 MG
PALBOGEN Palbociclib 125 MG
Generic name: palbociclib
The brand name of hydrogen Oncology: PALBOGEN
Drug classification: Antineoplastic
Pharmaceutical form: Capsule
Drug dose: 125 mg
packing: 21 tablets
Manufacturing plant: hydrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: Metastatic breast cancer
PALBOGEN Palbociclib 100 MG
PALBOGEN Palbociclib 100 MG
Generic name: palbociclib
The brand name of hydrogen Oncology: PALBOGEN
Drug classification: Antineoplastic
Pharmaceutical form: Capsule
Drug dose: 100 mg
packing: 21 tablets
Manufacturing plant: hydrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: Metastatic breast cancer
IMAGEN Imatinlb 100 MG
IMAGEN Imatinlb 100 MG
Generic name: Imatinib (as mesylate)
The brand name of hydrogen Oncology: Imagen
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 100 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- Acute lymphoblastic leukemia (ALL): Treatment of relapsed or refractory Philadelphia chromosome-positive (Ph+) ALL in adults
- Treatment of newly diagnosed Ph+ ALL in children (in combination with chemotherapy)
- Aggressive systemic mastocytosis: Treatment of aggressive systemic mastocytosis in adults without D816V c-Kit mutation (as determined by an approved test) or with c-Kit mutational status unknown
- Chronic myeloid leukemia (CML)
IBRUGEN Ibrutinib 140 MG
IBRUGEN Ibrutinib 140 MG
Generic name: Ibrutinib
The brand name of hydrogen Oncology: ibrugen
Drug classification: Antineoplastic
Pharmaceutical form: capsule
Drug dose: 140 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
- An aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men
- Fulvestrant in patients with disease progression following endocrine therapy
NILOGEN Nilotinib 150 MG
NILOGEN Nilotinib 150 MG
Generic name: Nilotinib (as hydrochloride monohydrate)
The brand name of hydrogen Oncology: Nilogen
Drug classification: Antineoplastic
Pharmaceutical form: capsule
Drug dose: 150 mg
packing: 30 capsules
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- Adult and pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
- Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib
- Pediatric patients ≥1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy
GEFIGEN Gefitinib 250 MG
GEFIGEN Gefitinib 250 MG
Generic name: Gefitinib
The brand name of hydrogen Oncology: Gefigen
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 250 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have:
- Epidermal growth factor receptor (EGFR) exon 19 deletions
- Exon 21 (L858R) substitution mutations
as detected by an FDA-approved test
IMAGEN Imatinlb 400 MG
IMAGEN Imatinlb 400 MG
Generic name: Imatinib (as mesylate)
The brand name of hydrogen Oncology: Imagen
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 400 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- Acute lymphoblastic leukemia (ALL): Treatment of relapsed or refractory Philadelphia chromosome-positive (Ph+) ALL in adults
- Treatment of newly diagnosed Ph+ ALL in children (in combination with chemotherapy)
- Aggressive systemic mastocytosis: Treatment of aggressive systemic mastocytosis in adults without D816V c-Kit mutation (as determined by an approved test) or with c-Kit mutational status unknown
- Chronic myeloid leukemia (CML)
SUNIGEN Sunitinib 50 MG
SUNIGEN Sunitinib 50 MG
Generic name: Sunitinib (as malate or as base)
The brand name of hydrogen Oncology: Sunigen
Drug classification: Antineoplastic
Pharmaceutical form: capsule
Drug dose: 50 mg
packing: 30 capsule
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- The treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate
- The treatment of advanced renal cell carcinoma (RCC)
- The adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy
- The treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease
SORAFIGEN Sotaenib 200 MG
SORAFIGEN Sotaenib 200 MG
Generic name: Sorafenib
The brand name of hydrogen Oncology: sorafigen
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 200 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications:
- Unresectable hepatocellular carcinoma
- Advanced renal cell carcinoma
- Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
RUXOGEN Ruxolitinib 15 MG
RUXOGEN Ruxolitinib 15 MG
Generic name: Ruxolitinib
The brand name of hydrogen Oncology: RUXOGEN
Drug classification: Antineoplastic
Pharmaceutical form: tablet
Drug dose: 15 mg
packing: 30 tablets
Manufacturing plant: hyrogen Oncology
Brand owner: hydrogen Oncology
The country of the brand owner: iraq
Indications: for the treatment of certain types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).
Indications:
- Myelofibrosis
- Polycythemia vera
- Graft-versus-host disease (GVHD)